Elevated Tumor Mutational Burden and Prolonged Clinical Response to Anti-PD-L1 Antibody in Platinum-resistant Recurrent Ovarian Cancer

Overview

Journal Gynecol Oncol Rep

Publisher Elsevier

Date 2017 Jul 25

PMID 28736741

Citations 15

Authors

Christopher B Morse

Julia A Elvin

Laurie M Gay

John B Liao

Affiliations

Soon will be listed here.

Abstract

•We report an ovarian cancer patient with a prolonged response to immunotherapy.•Comprehensive genomic profiling may detect patients who benefit from immunotherapy.•Mutational burden thresholds for ovarian cancer may be lower than other cancers.

Citing Articles

A patient stratification signature mirrors the immunogenic potential of high grade serous ovarian cancers.

Berry L, Pullikuth A, Stearns K, Wang Y, Wagner C, Chou J J Transl Med. 2024; 22(1):1048.

PMID: 39568014 PMC: 11577735. DOI: 10.1186/s12967-024-05846-9.

Limitations and potential of immunotherapy in ovarian cancer.

Kumar S, Acharya S, Karthikeyan M, Biswas P, Kumari S Front Immunol. 2024; 14:1292166.

PMID: 38264664 PMC: 10803592. DOI: 10.3389/fimmu.2023.1292166.

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.

Tassi E, Bergamini A, Wignall J, SantAngelo M, Brunetto E, Balestrieri C Front Immunol. 2023; 14:1212444.

PMID: 37868997 PMC: 10585363. DOI: 10.3389/fimmu.2023.1212444.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.

Disis M, Adams S, Bajpai J, Butler M, Curiel T, Dodt S J Immunother Cancer. 2023; 11(6).

PMID: 37295818 PMC: 10277149. DOI: 10.1136/jitc-2022-006624.

Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.

Hada T, Miyamoto M, Ohtsuka Y, Suminokura J, Ito T, Kishimoto N Diagn Pathol. 2023; 18(1):49.

PMID: 37081552 PMC: 10120221. DOI: 10.1186/s13000-023-01340-w.

References

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T . Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015; 33(34):4015-22. DOI: 10.1200/JCO.2015.62.3397. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Ross J, Ali S, Wang K, Palmer G, Yelensky R, Lipson D . Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol. 2013; 130(3):554-9. DOI: 10.1016/j.ygyno.2013.06.019. View

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood A . Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011; 306(14):1557-65. PMC: 4159096. DOI: 10.1001/jama.2011.1456. View

Frampton G, Fichtenholtz A, Otto G, Wang K, Downing S, He J . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. PMC: 5710001. DOI: 10.1038/nbt.2696. View

10.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

11.

Liu Y, Yasukawa M, Chen K, Hu L, Broaddus R, Ding L . Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol. 2015; 1(4):486-94. PMC: 4608536. DOI: 10.1001/jamaoncol.2015.1432. View